About BEYOND BARRIERS THERAPEUTICS, INC.
Beyond Barriers Therapeutics is a clinical-stage biotechnology company developing BBT-101, a first-of-its-kind intranasal therapy for mild and moderate traumatic brain injuries (concussions). The therapy is designed to be fast, field-deployable, and effective, with a focus on rapid intervention after injury.
Development of BBT-101, an intranasal therapy for mild and moderate traumatic brain injuries (mTBI)Patented nose-to-brain delivery system for faster and more targeted therapeutic effectsRepurposing of N-acetylcysteine (NAC) with a 50+ year safety recordExploration of future indications including pediatric concussions, seizures, strokes, and blast injuryOptimized formula with 10x greater bioavailability and 4x faster action compared to oral delivery
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| INTRANASAL TREATMENT FOR MILD TRAUMATIC BRAIN INJURY (BROAD AGENCY ANNOUNCEMENT NUMBER SO190192) | Department of Defense | $1.9M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to BEYOND BARRIERS THERAPEUTICS, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.